Promising study aims to spare breast cancer patients from unnecessary chemo

NCT ID NCT03716180

First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 25 times

Summary

This study looks at women with HER2-positive breast cancer who had a complete response to a three-drug combination before surgery. The goal is to see if they can safely skip chemotherapy after surgery and only receive two antibody drugs. About 100 participants are enrolled to test this approach and collect blood and tissue samples.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • DF/BWCC at Milford Regional Medical Center

    Milford, Massachusetts, 01757, United States

  • DF/BWCC in clinical affiliation with South Shore Hospital

    South Weymouth, Massachusetts, 02190, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

Conditions

Explore the condition pages connected to this study.